Figure 2.

Interface hepatitis in PBC. At presentation, this patient was AMA‐positive with a cholestatic liver chemical profile. Because of an ALT that was >5× ULN alongside an immunoglobulin G level of 20 g/L and SMA reactivity, liver biopsy was performed. This demonstrated significant interface hepatitis. However, treatment with UDCA alone led to a complete normalization of liver chemistry and immunoglobulins at 6 months. Notably, when patients in a clinical trial of PBC were identified as having potential AIH overlap retrospectively, it was clear that the clinical course on UDCA treatment was not distinct compared with classical PBC patients, nor was outcome.13